IL-10 attenuates metabolic dysfunction–associated steatotic liver disease via modulation of hepatic responses to lipotoxicity
JCI Insight · 22.06.2026 · 11 (12)
DOI: 10.1172/jci.insight.200231 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 23.04.2026. Verfasst von Akira Kado und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine. Hauptthemen laut MEDLINE: Interleukin-10, Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Lipotoxicity associated with metabolic dysfunction–associated steatotic liver disease (MASLD) causes dysregulated fatty acid (FA) and glucose metabolism, inducing cellular energy imbalance, oxidative stress (OS), and hepatocellular injury. IL-10 is altered in MASLD, including increased IL-10 transcripts in peripheral immune cells; however, its role in hepatic responses to lipotoxic stress remains unclear. We evaluated whether IL-10 treatment attenuates lipotoxic injury and MASLD-related phenotypes in vivo and in vitro to reveal MASLD treatment strategies. As MASLD models, mice fed a high-fat diet and in vitro normal human hepatocytes under palmitic acid exposure were treated with IL-10, along with confirmatory experiments in HepG2 cells. We assessed FA and glucose metabolism, OS, and apoptosis with histological changes and mechanisms related to hepatocellular viability/metabolic activity and stress-responsive survival signaling in vitro. IL-10 modulated FA synthesis and β-oxidation, reducing lipid accumulation, and IL-10 altered glucose metabolic pathways, consistent with improved glucose handling under lipotoxic stress. Furthermore, IL-10 reduced OS and cell death markers while enhancing antioxidant responses, consistent with hepatocellular protection. These data suggest that IL-10 attenuates lipotoxic injury by modulating hepatic response pathways, thereby improving MASLD-related phenotypes, and support the potential of IL-10 as a therapeutic target for MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine.
- Division for Health Service Promotion.
- Department of Infection Control and Prevention, Graduate School of Medicine.
- Department of Infectious Diseases, Graduate School of Medicine; and.
- Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- Division of Infection Control and Prevention, Education Research Center, Tokyo Health Care University, Higashigotanda, Shinagawa-ku, Tokyo, Japan.
Förderung
- JSPS KAKENHI
Zitieren
APA
Kado, A., Okushin, K., Tsutsumi, T., Kishida, T., Ikeuchi, K., Yotsuyanagi, H., Moriya, K., Koike, K., & Fujishiro, M. (2026). IL-10 attenuates metabolic dysfunction–associated steatotic liver disease via modulation of hepatic responses to lipotoxicity. JCI Insight, 11(12). https://doi.org/10.1172/jci.insight.200231
Vancouver
Kado A, Okushin K, Tsutsumi T, Kishida T, Ikeuchi K, Yotsuyanagi H, et al. IL-10 attenuates metabolic dysfunction–associated steatotic liver disease via modulation of hepatic responses to lipotoxicity. JCI Insight. 2026;11(12). doi:10.1172/jci.insight.200231
BibTeX
@article{Kado2026,
author = {Kado, Akira and Okushin, Kazuya and Tsutsumi, Takeya and Kishida, Toshiyuki and Ikeuchi, Kazuhiko and Yotsuyanagi, Hiroshi and Moriya, Kyoji and Koike, Kazuhiko and Fujishiro, Mitsuhiro},
title = {IL-10 attenuates metabolic dysfunction–associated steatotic liver disease via modulation of hepatic responses to lipotoxicity},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {12},
doi = {10.1172/jci.insight.200231}
}
EUVIMED